JP2023505522A5 - - Google Patents

Info

Publication number
JP2023505522A5
JP2023505522A5 JP2022534671A JP2022534671A JP2023505522A5 JP 2023505522 A5 JP2023505522 A5 JP 2023505522A5 JP 2022534671 A JP2022534671 A JP 2022534671A JP 2022534671 A JP2022534671 A JP 2022534671A JP 2023505522 A5 JP2023505522 A5 JP 2023505522A5
Authority
JP
Japan
Prior art keywords
sequence
pharmaceutical composition
nucleic acid
recombinant nucleic
ncatp9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505522A (ja
Filing date
Publication date
Priority claimed from CN201911250082.4A external-priority patent/CN113025633B/zh
Application filed filed Critical
Publication of JP2023505522A publication Critical patent/JP2023505522A/ja
Publication of JP2023505522A5 publication Critical patent/JP2023505522A5/ja
Pending legal-status Critical Current

Links

JP2022534671A 2019-12-09 2020-12-09 Nadhデヒドロゲナーゼタンパク質でレーベル遺伝性視神経症を治療するための組成物及び方法 Pending JP2023505522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911250082.4A CN113025633B (zh) 2019-12-09 2019-12-09 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CN201911250082.4 2019-12-09
PCT/CN2020/134859 WO2021115317A1 (en) 2019-12-09 2020-12-09 Compositions and methods for treating leber's hereditary optic neuropathy with nadh dehydrogenase proteins

Publications (2)

Publication Number Publication Date
JP2023505522A JP2023505522A (ja) 2023-02-09
JP2023505522A5 true JP2023505522A5 (https=) 2023-12-08

Family

ID=76329564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534671A Pending JP2023505522A (ja) 2019-12-09 2020-12-09 Nadhデヒドロゲナーゼタンパク質でレーベル遺伝性視神経症を治療するための組成物及び方法

Country Status (10)

Country Link
US (2) US11357869B2 (https=)
EP (1) EP4073244A4 (https=)
JP (1) JP2023505522A (https=)
KR (1) KR20220112262A (https=)
CN (2) CN113025633B (https=)
AU (1) AU2020399898A1 (https=)
BR (1) BR112022010321A2 (https=)
CA (1) CA3160809A1 (https=)
MX (1) MX2022006949A (https=)
WO (1) WO2021115317A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113528510A (zh) 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
SG11202101032VA (en) 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Ltd Company Compositions and methods for treating leber's hereditary optic neuropathy
AR126727A1 (es) * 2021-08-06 2023-11-08 Wuhan Neurophth Biotechnology Ltd Company Composición y método para tratar la neuropatía óptica hereditaria de leber causada por la mutación nd4
CN115927401B (zh) * 2021-08-23 2025-05-16 纽福斯(苏州)生物科技有限公司 编码nadh泛醌氧化还原酶4号亚基的核酸及其用途
CN114213549B (zh) * 2021-12-24 2024-01-05 上海生物芯片有限公司 定位于线粒体的融合蛋白、接头及其用途
JP2026501611A (ja) * 2022-12-29 2026-01-16 エッジーン インコーポレイテッド レーベル遺伝性視神経症のミトコンドリア塩基変異矯正システム

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
AU2668897A (en) 1996-04-19 1997-11-12 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5814451A (en) * 1997-01-17 1998-09-29 Incyte Pharmaceuticals, Inc. Subunits of NADH dehydrogenase
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
CN1270222A (zh) * 2000-03-17 2000-10-18 国家人类基因组南方研究中心 一种新的人辅酶ⅰ亚基异构体蛋白及其编码序列
US20020132978A1 (en) 2000-03-21 2002-09-19 Hans-Peter Gerber VEGF-modulated genes and methods employing them
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
BRPI0511764B8 (pt) 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
EP1877559B1 (en) * 2005-04-18 2010-10-13 Mitomics Inc. Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US20130022979A1 (en) 2005-04-18 2013-01-24 Genesis Genomics Inc. 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER
PT1880008E (pt) 2005-05-03 2015-08-27 Inserm Inst Nat De La Santé Et De La Rech Médicale Expressão de proteína mitocondrial através de uma abordagem alotópica melhorada
AU2007324073A1 (en) 2006-10-23 2008-05-29 John Guy Suppression of mitochondrial oxidative stress
WO2008155397A2 (en) 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
WO2010040901A1 (en) * 2008-10-07 2010-04-15 Pierre Rustin Alternative oxidase and uses thereof
CA2962219C (en) 2008-10-22 2020-08-25 Quark Pharmaceuticals, Inc. Methods for treating eye disorders
RU2011137486A (ru) * 2009-03-27 2013-05-10 Митомикс Инк. Аберрантная митохондриальная днк, ассоциированные с ней слитые транскрипты, продукты трансляции и гибрадизационные зонды
WO2011094198A1 (en) 2010-01-28 2011-08-04 The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
CN102517304B (zh) 2011-12-16 2013-08-28 中国农业科学院生物技术研究所 重组葡萄糖氧化酶的优化基因及其表达载体和应用
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US20160289674A1 (en) 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
CN102634527B (zh) 2012-04-11 2013-11-06 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
SG11201702116VA (en) 2014-09-17 2017-04-27 Univ Iowa Res Found Viral rna segments as immunomodulatory agents and vaccine components
CN104450747B (zh) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂
AU2016291778B2 (en) 2015-07-13 2021-05-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
EP3548039B1 (en) 2016-12-04 2023-07-19 Alavi Khorassani Moghadam, Marcel Victor Ribavirin for use in the treatment of a mitochondrial disease
US20180207293A1 (en) 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
WO2019033119A1 (en) 2017-08-11 2019-02-14 Unity Biotechnology, Inc. TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
CN109970861B (zh) * 2017-12-27 2021-06-11 武汉纽福斯生物科技有限公司 一种靶向线粒体的nd4融合蛋白及其制备方法和应用
US20210163898A1 (en) 2018-04-16 2021-06-03 The Children's Hospital Of Philadelphia Mitochondrial rna import for treating mitochondrial disease
CA3103231A1 (en) 2018-06-11 2019-12-19 Serge FITOUSSI Recombinant aav vectors and methods of using the same
WO2020000641A1 (zh) 2018-06-29 2020-01-02 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
WO2020010491A1 (zh) 2018-07-09 2020-01-16 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN110846392A (zh) 2018-08-20 2020-02-28 武汉纽福斯生物科技有限公司 一种重组腺相关病毒或含其的试剂盒及其应用
CN111068071A (zh) 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
CN113528510A (zh) * 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
CN111073899B (zh) 2018-10-19 2021-01-01 武汉纽福斯生物科技有限公司 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
SG11202101032VA (en) * 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Ltd Company Compositions and methods for treating leber's hereditary optic neuropathy

Similar Documents

Publication Publication Date Title
JP2023505522A5 (https=)
JP2023522249A5 (https=)
JP2020203894A5 (https=)
US9700595B2 (en) Liquid formulation of a fusion protein comprising TNFR and Fc region
ES2246177B1 (es) Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
JP2022543038A5 (https=)
FI4101864T3 (fi) Polypeptidi ja sen valmistusmenetelmä ja sen käyttö
JP2021512126A5 (https=)
JP2021513863A5 (https=)
FI4206216T3 (fi) Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi
CA3028683A1 (en) Pegylated porcine interferon and methods of use thereof
JP2020169191A5 (https=)
US20200397871A1 (en) Treatment of middle east respiratory syndrome coronavirus
BR112021008832A2 (pt) Proteínas de núcleo de mininucleossoma e uso em distribuição de ácido nucleico
JP2023542297A5 (https=)
CA3185425A1 (en) Tetanus vaccine platform for embedding covid-19 vaccine
JP5981141B2 (ja) 多臓器不全症候群(mods)の予防および/または処置のためのインターロイキン−22の使用
JP2023522154A5 (https=)
JP2002527483A (ja) アデノウィルスベクターを投与する方法
JP2023510784A5 (https=)
JP2024519904A5 (https=)
ES2337663T3 (es) Compuestos peptidicos que se unen selectivamente a p-selectina.
JP2020019765A (ja) 高濃縮アルファ−1プロテイナーゼインヒビターを含む組成物及びそれを得るための方法
JP2024529033A5 (https=)
CN117899223A (zh) 以nup35基因和或以nup35蛋白作为作用靶点的物质的应用及组合物